TY - JOUR
T1 - HDL functionality in familial hypercholesterolemia
T2 - effects of treatment modalities and pharmacological interventions
AU - Ganjali, Shiva
AU - Momtazi-Borojeni, Amir Abbas
AU - Banach, Maciej
AU - Kovanen, Petri T.
AU - Gotto, Antonio M.
AU - Sahebkar, Amirhossein
PY - 2018/1
Y1 - 2018/1
N2 - Recent studies have demonstrated that assessment of high-density lipoprotein (HDL) functionality indices, instead of HDL cholesterol measurement, is a more robust tool for the evaluation of the functional status of HDL and cardiovascular risk. There are qualitative abnormalities of HDL particles in familial hypercholesterolemia (FH) patients that might represent potential therapeutic targets. Despite the potential promise of optimizing HDL functionality for the treatment of FH, there has been no prior comprehensive review focusing on the impact of different lipid-modifying therapies on HDL functionality in FH patients. In the present review, we aim to fulfill this gap and provide a concise summary on the impact of different lipid-modifying therapies on HDL functionality in FH.
AB - Recent studies have demonstrated that assessment of high-density lipoprotein (HDL) functionality indices, instead of HDL cholesterol measurement, is a more robust tool for the evaluation of the functional status of HDL and cardiovascular risk. There are qualitative abnormalities of HDL particles in familial hypercholesterolemia (FH) patients that might represent potential therapeutic targets. Despite the potential promise of optimizing HDL functionality for the treatment of FH, there has been no prior comprehensive review focusing on the impact of different lipid-modifying therapies on HDL functionality in FH patients. In the present review, we aim to fulfill this gap and provide a concise summary on the impact of different lipid-modifying therapies on HDL functionality in FH.
UR - http://www.scopus.com/inward/record.url?scp=85030720228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030720228&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2017.09.014
DO - 10.1016/j.drudis.2017.09.014
M3 - Review article
C2 - 28986138
AN - SCOPUS:85030720228
VL - 23
SP - 171
EP - 180
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 1
ER -